The people behind Syngenis.

An internationally recognised expert in DNA and RNA chemistry, oligonucleotide therapeutics and nucleic acid modification, and the founder of Syngenis. He is Professor and Head of the Precision Nucleic Acid Therapeutics Group within Murdoch University's Personalised Medicine Centre and the Perron Institute for Neurological and Translational Science. With more than two decades of experience across state of the art synthesis facilities and long term research programs, over 115 peer reviewed papers, a specialist scientific text and multiple patents, his work spans antisense oligonucleotides, RNA therapeutics, chemical modification and delivery, across neurology, oncology and metabolic disease. He is also co founder and director of ProGenis Pharmaceuticals. He provides deep scientific and technical leadership across manufacturing, discovery and therapeutic strategy.

A practising radiologist and experienced healthcare executive with a strong background in medical technology, diagnostics and governance. Chair of the WA National Imaging Facility Advisory Board and until recently Chairman of Resonance Health (ASX:RHT), with board experience across mergers and acquisitions, capital markets, and the scaling of technology enabled healthcare businesses. His clinical background gives practical insight into how diagnostic technologies are adopted, validated and used in real healthcare settings, and he brings strong governance discipline to the board.

A biotechnology executive experienced in forming and scaling science led businesses across diagnostics and life sciences. A founding director of Nexsen (ASX:NXN) and the inaugural Managing Director of Singular Health Group (ASX:SHG), he has structured collaboration and licence agreements, progressed early research into commercial technologies, and secured up to approximately 7 million dollars in non dilutive funding for early stage technology. He is responsible for executing the company's strategy across infrastructure, development pathways, commercial partnerships and public market readiness.

An experienced business executive and director with more than thirty years in company formation, governance, growth strategy and operational management across ASX listed and private companies, including RLF AgTech (ASX:RLF), a founding board role at McLaren Minerals (ASX:MML), and a founding directorship of Nexsen (ASX:NXN). He provides practical commercial oversight, ASX governance experience and an execution focused perspective as the company scales.

Leads DNA and RNA production and laboratory operations across research grade and GMP aligned environments, overseeing the technical capability at the heart of the manufacturing pillar.